Published in
Elsevier, Annals of Oncology, 3(25), p. 700-706, 2014
Links
- Elsevier
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [hdl.handle.net]
- [www.zora.uzh.ch] | PDF
- [doc.rero.ch] | PDF
- [europepmc.org] | PDF
- [www.researchgate.net] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study
Journal article published in 2014 by
D. Schadendorf,
M. M. Amonkar,
M. Milhem,
K. Grotzinger,
L. V. Demidov,
P. Rutkowski,
Claus Garbe 
,
R. Dummer,
J. C. Hassel,
P. Wolter,
P. Mohr,
U. Trefzer,
C. Lefeuvre-Plesse,
A. Rutten,
N. Steven
and other authors.
,
R. Dummer,
J. C. Hassel,
P. Wolter,
P. Mohr,
U. Trefzer,
C. Lefeuvre-Plesse,
A. Rutten,
N. Steven
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
We report the first quality-of-life assessment of a MEK inhibitor in metastatic melanoma from a phase III study. Trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. Less functional impairment, smaller declines in health status, and less exacerbation of symptoms were observed with trametinib.